Your browser doesn't support javascript.
loading
Dysregulated lipid metabolism networks modulate T-cell function in people with relapsing-remitting multiple sclerosis.
Martin-Gutierrez, Lucia; Waddington, Kirsty E; Maggio, Annalisa; Coelewij, Leda; Oppong, Alexandra E; Yang, Nina; Adriani, Marsilio; Nytrova, Petra; Farrell, Rachel; Pineda-Torra, Inés; Jury, Elizabeth C.
Afiliación
  • Martin-Gutierrez L; Centre for Rheumatology, Division of Medicine, University College London, UK.
  • Waddington KE; Centre for Rheumatology, Division of Medicine, University College London, UK.
  • Maggio A; Centre for Rheumatology, Division of Medicine, University College London, UK.
  • Coelewij L; Centre for Rheumatology, Division of Medicine, University College London, UK.
  • Oppong AE; Centre for Rheumatology, Division of Medicine, University College London, UK.
  • Yang N; Centre for Rheumatology, Division of Medicine, University College London, UK.
  • Adriani M; Centre for Rheumatology, Division of Medicine, University College London, UK.
  • Nytrova P; Department of Neurology and Centre of Clinical, Neuroscience, First Faculty of Medicine, General University Hospital and First Faculty of Medicine, Charles University in Prague, Czech Republic.
  • Farrell R; Department of Neuroinflammation, University College London and Institute of Neurology and National Hospital of Neurology and Neurosurgery, UK.
  • Pineda-Torra I; Centre for Experimental & Translational Medicine, Division of Medicine, University College London, UK.
  • Jury EC; Centre for Rheumatology, Division of Medicine, University College London, UK.
Clin Exp Immunol ; 217(2): 204-218, 2024 Jul 12.
Article en En | MEDLINE | ID: mdl-38625017
ABSTRACT
Altered cholesterol, oxysterol, sphingolipid, and fatty acid concentrations are reported in blood, cerebrospinal fluid, and brain tissue of people with relapsing-remitting multiple sclerosis (RRMS) and are linked to disease progression and treatment responses. CD4 + T cells are pathogenic in RRMS, and defective T-cell function could be mediated in part by liver X receptors (LXRs)-nuclear receptors that regulate lipid homeostasis and immunity. RNA-sequencing and pathway analysis identified that genes within the 'lipid metabolism' and 'signalling of nuclear receptors' pathways were dysregulated in CD4 + T cells isolated from RRMS patients compared with healthy donors. While LXRB and genes associated with cholesterol metabolism were upregulated, other T-cell LXR-target genes, including genes involved in cellular lipid uptake (inducible degrader of the LDL receptor, IDOL), and the rate-limiting enzyme for glycosphingolipid biosynthesis (UDP-glucosylceramide synthase, UGCG) were downregulated in T cells from patients with RRMS compared to healthy donors. Correspondingly, plasma membrane glycosphingolipids were reduced, and cholesterol levels increased in RRMS CD4 + T cells, an effect partially recapitulated in healthy T cells by in vitro culture with T-cell receptor stimulation in the presence of serum from RRMS patients. Notably, stimulation with LXR-agonist GW3965 normalized membrane cholesterol levels, and reduced proliferation and IL17 cytokine production in RRMS CD4 + T-cells. Thus, LXR-mediated lipid metabolism pathways were dysregulated in T cells from patients with RRMS and could contribute to RRMS pathogenesis. Therapies that modify lipid metabolism could help restore immune cell function.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfocitos T CD4-Positivos / Esclerosis Múltiple Recurrente-Remitente / Metabolismo de los Lípidos / Receptores X del Hígado Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Exp Immunol Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfocitos T CD4-Positivos / Esclerosis Múltiple Recurrente-Remitente / Metabolismo de los Lípidos / Receptores X del Hígado Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Exp Immunol Año: 2024 Tipo del documento: Article